Karim Fizazi, MD, PhD, provides an overview of advances in treatment of metastatic castrate-resistant prostate cancer.
Metastatic Castrate-Resistant Prostate Cancer Treatment: Updates on Use of Darolutamide
An oncologist explains treatment selection and the systemic therapy options available for patients with metastatic castrate-resistant prostate cancer.
Dr. Karim Fizazi describes the use of next generation androgen receptor inhibitors in treatment of metastatic castrate-resistant prostate cancer.
A key opinion leader discusses impact of ADTs on brain and cognitive function in men with prostate cancer.
Karim Fizazi, MD, PhD, reviews darolutamide data in prostate cancer, including data from phase II clinical trial, ODENZA.
An expert discusses the future of metastatic castrate-resistant prostate cancer management.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
